149 related articles for article (PubMed ID: 21056499)
1. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy.
Fung J; Seto WK; Lai CL; Yuen J; Wong DK; Yuen MF
J Hepatol; 2011 Feb; 54(2):195-200. PubMed ID: 21056499
[TBL] [Abstract][Full Text] [Related]
2. [Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B].
Kim KH; Na IH; Cha JM; Cho YK; Park SY; Kim HP; Song CS; Heo J; Cho M
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):284-92. PubMed ID: 14695695
[TBL] [Abstract][Full Text] [Related]
3. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
4. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
Kumar M; Sarin SK; Hissar S; Pande C; Sakhuja P; Sharma BC; Chauhan R; Bose S
Gastroenterology; 2008 May; 134(5):1376-84. PubMed ID: 18471514
[TBL] [Abstract][Full Text] [Related]
5. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
[TBL] [Abstract][Full Text] [Related]
6. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
7. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
8. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of liver biopsy in Egyptian HBeAg-negative chronic hepatitis B patients at initial presentation: implications for therapy.
El-Zayadi AR; Badran HM; Saied A; Shawky S; Attia Mel-D; Zalata K
Am J Gastroenterol; 2009 Apr; 104(4):906-11. PubMed ID: 19293791
[TBL] [Abstract][Full Text] [Related]
10. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease.
Bozkaya H; Bozdayi M; Türkyilmaz R; Sarioglu M; Cetinkaya H; Cinar K; Köse K; Yurdaydin C; Uzunalimoglu O
Hepatogastroenterology; 2000; 47(36):1675-9. PubMed ID: 11149030
[TBL] [Abstract][Full Text] [Related]
11. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
12. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
13. e-antigen-negative chronic hepatitis B in Bangladesh.
Ahmad N; Alam S; Mustafa G; Adnan AB; Baig RH; Khan M
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):379-82. PubMed ID: 18693173
[TBL] [Abstract][Full Text] [Related]
14. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B.
Alam S; Ahmad N; Mustafa G; Shrestha A; Alam AK; Khan M
Liver Int; 2011 Jul; 31(6):824-30. PubMed ID: 21645213
[TBL] [Abstract][Full Text] [Related]
16. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
17. [Characteristic of liver pathology in HBeAg-positive and HBeAg-negative chronic hepatitis B patients with mildly elevated ALT].
Liu SQ; Zhu XJ; Sun XH; Li M; Gao YQ
Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):348-52. PubMed ID: 22971279
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
[TBL] [Abstract][Full Text] [Related]
19. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B.
Croagh CM; Bell SJ; Slavin J; Kong YX; Chen RY; Locarnini S; Desmond PV
Liver Int; 2010 Sep; 30(8):1115-22. PubMed ID: 20492511
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.
Chan HL; Leung NW; Hussain M; Wong ML; Lok AS
Hepatology; 2000 Mar; 31(3):763-8. PubMed ID: 10706570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
